Equities analysts expect Enanta Pharmaceuticals Inc (NASDAQ:ENTA) to report $0.57 earnings per share for the current fiscal quarter, according to Zacks. Four analysts have provided estimates for Enanta Pharmaceuticals’ earnings. The highest EPS estimate is $1.10 and the lowest is $0.34. Enanta Pharmaceuticals reported earnings of $1.30 per share in the same quarter last year, which indicates a negative year over year growth rate of 56.2%. The firm is expected to announce its next earnings report on Monday, November 25th.
On average, analysts expect that Enanta Pharmaceuticals will report full year earnings of $2.37 per share for the current financial year, with EPS estimates ranging from $2.11 to $2.88. For the next year, analysts expect that the company will report earnings of ($0.72) per share, with EPS estimates ranging from ($2.41) to $0.81. Zacks Investment Research’s EPS calculations are a mean average based on a survey of sell-side research firms that cover Enanta Pharmaceuticals.
Enanta Pharmaceuticals (NASDAQ:ENTA) last posted its quarterly earnings data on Tuesday, August 6th. The biotechnology company reported $0.33 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.06 by $0.27. The business had revenue of $44.40 million for the quarter, compared to analysts’ expectations of $46.98 million. Enanta Pharmaceuticals had a return on equity of 15.16% and a net margin of 29.22%. The business’s revenue was down 22.5% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.97 earnings per share.
A number of hedge funds have recently bought and sold shares of the stock. Rhumbline Advisers increased its position in Enanta Pharmaceuticals by 2.4% during the 3rd quarter. Rhumbline Advisers now owns 50,889 shares of the biotechnology company’s stock valued at $3,057,000 after buying an additional 1,214 shares in the last quarter. Virginia Retirement Systems ET AL increased its position in Enanta Pharmaceuticals by 7.1% during the 3rd quarter. Virginia Retirement Systems ET AL now owns 10,600 shares of the biotechnology company’s stock valued at $637,000 after buying an additional 700 shares in the last quarter. Strs Ohio increased its position in Enanta Pharmaceuticals by 7.3% during the 3rd quarter. Strs Ohio now owns 11,800 shares of the biotechnology company’s stock valued at $708,000 after buying an additional 800 shares in the last quarter. Robeco Institutional Asset Management B.V. bought a new position in Enanta Pharmaceuticals during the 3rd quarter valued at approximately $48,000. Finally, Pacer Advisors Inc. increased its position in Enanta Pharmaceuticals by 31.4% during the 3rd quarter. Pacer Advisors Inc. now owns 5,170 shares of the biotechnology company’s stock valued at $311,000 after buying an additional 1,234 shares in the last quarter. 88.61% of the stock is owned by institutional investors.
Shares of Enanta Pharmaceuticals stock traded down $0.72 during trading on Monday, hitting $59.55. 101,205 shares of the stock traded hands, compared to its average volume of 216,990. The stock has a market cap of $1.20 billion, a price-to-earnings ratio of 17.11 and a beta of 0.93. The firm’s fifty day moving average is $64.19 and its 200-day moving average is $79.21. Enanta Pharmaceuticals has a 52 week low of $57.15 and a 52 week high of $106.80.
Enanta Pharmaceuticals Company Profile
Enanta Pharmaceuticals, Inc, a biotechnology company, focuses on the research and development of small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, non-alcoholic steatohepatitis, primary biliary cholangitis, and hepatitis B virus.
Recommended Story: Municipal Bonds
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Enanta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.